Anebulo Pharmaceuticals, Inc. (ANEB) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
C/O ANEBULO PHARMACEUTICALS, INC. LAKEWAY, TX 78734 |
| State of Incorp. | DE |
| Fiscal Year End | June 30 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 3/31/2025 MRQ | 12/31/2024 MRQ | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 14,998,467 | 3,094,200 | 11,247,403 | 14,548,471 | 19,985,645 | |||
| Cash and cash equivalent | 14,998,467 | 3,094,200 | 11,247,403 | 14,548,471 | 19,985,645 | |||
| Prepaid expense | 366,266 | 413,790 | 422,748 | 1,030,960 | 1,123,411 | |||
| Other undisclosed current assets | 30,756 | |||||||
| Total current assets: | 15,395,489 | 3,507,990 | 11,670,151 | 15,579,431 | 21,109,056 | |||
| Noncurrent Assets | ||||||||
| Other noncurrent assets | 445,731 | 565,124 | ||||||
| Total noncurrent assets: | 445,731 | 565,124 | ||||||
| Other undisclosed assets | 544,435 | |||||||
| TOTAL ASSETS: | 15,841,220 | 4,073,114 | 11,670,151 | 15,579,431 | 21,653,491 | |||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities | 878,799 | 260,583 | 1,068,801 | 512,531 | 241,633 | |||
| Accounts payable | 319,515 | 156,426 | 534,545 | 380,828 | 110,048 | |||
| Accrued liabilities | 559,284 | 104,157 | 534,256 | 131,703 | 131,585 | |||
| Total current liabilities: | 878,799 | 260,583 | 1,068,801 | 512,531 | 241,633 | |||
| Noncurrent Liabilities | ||||||||
| Total liabilities: | 878,799 | 260,583 | 1,068,801 | 512,531 | 241,633 | |||
| Equity | ||||||||
| Equity, attributable to parent | 14,962,421 | 3,812,531 | 10,601,350 | 15,066,900 | 21,411,858 | |||
| Common stock | 41,086 | 25,934 | 25,634 | 23,345 | 23,345 | |||
| Additional paid in capital | 84,988,845 | 69,190,341 | 67,777,757 | 60,513,258 | 60,032,597 | |||
| Accumulated deficit | (70,067,510) | (65,403,744) | (57,202,041) | (45,469,703) | (38,644,084) | |||
| Total equity: | 14,962,421 | 3,812,531 | 10,601,350 | 15,066,900 | 21,411,858 | |||
| TOTAL LIABILITIES AND EQUITY: | 15,841,220 | 4,073,114 | 11,670,151 | 15,579,431 | 21,653,491 | |||
Income Statement (P&L) (USD)
| 3/31/2025 TTM | 12/31/2024 TTM | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | ||
|---|---|---|---|---|---|---|---|
| Gross profit: | 700,000 | ||||||
| Operating expenses | (8,004,893) | (8,308,755) | (11,783,599) | (6,831,174) | (3,613,753) | ||
| Other undisclosed operating loss | (700,000) | ||||||
| Operating loss: | (8,004,893) | (8,308,755) | (11,783,599) | (6,831,174) | (3,613,753) | ||
| Nonoperating income (expense) | 337,616 | 107,052 | 51,261 | 5,555 | (324) | ||
| Investment income, nonoperating | 68,084 | 1,020 | |||||
| Other nonoperating income (expense) | 2,085 | 9,260 | (41,146) | (1,777) | (1,344) | ||
| Interest and debt expense | (119,393) | (11,767) | |||||
| Other undisclosed loss from continuing operations before equity method investments, income taxes | (151,230) | ||||||
| Loss from continuing operations before equity method investments, income taxes: | (7,937,900) | (8,201,703) | (11,732,338) | (6,825,619) | (3,625,844) | ||
| Other undisclosed income from continuing operations before income taxes | 12,091 | ||||||
| Loss from continuing operations: | (7,937,900) | (8,201,703) | (11,732,338) | (6,825,619) | (3,613,753) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | (6,825,619) | (3,613,753) | |
| Net loss: | (7,937,900) | (8,201,703) | (11,732,338) | (6,825,619) | (3,613,753) | ||
| Other undisclosed net income (loss) attributable to parent | 270,623 | (26,638,801) | |||||
| Net loss attributable to parent: | (7,667,277) | (8,201,703) | (11,732,338) | (6,825,619) | (30,252,554) | ||
| Preferred stock dividends and other adjustments | (8,208,393) | ||||||
| Net loss available to common stockholders, diluted: | (7,667,277) | (8,201,703) | (11,732,338) | (6,825,619) | (38,460,947) | ||
Comprehensive Income (USD)
| 3/31/2025 TTM | 12/31/2024 TTM | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | ||
|---|---|---|---|---|---|---|---|
| Net loss: | (7,937,900) | (8,201,703) | (11,732,338) | (6,825,619) | (3,613,753) | ||
| Comprehensive loss, net of tax, attributable to parent: | (7,937,900) | (8,201,703) | (11,732,338) | (6,825,619) | (3,613,753) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.